Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 1999  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Resource Links
  »  Similar in PUBMED
 »Related articles
  »  Article in PDF (654 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

  In this Article
 »  Abstract
 » Methods
 » Results
 » Discussion
 »  References
 »  Article Tables

 Article Access Statistics
    PDF Downloaded14    
    Comments [Add]    

Recommend this journal


Table of Contents    
Year : 2021  |  Volume : 69  |  Issue : 6  |  Page : 1645-1649

Impact of Pre-Stroke Antiplatelet Use on 3-Month Outcome After Ischemic Stroke

1 Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India
2 Department of Neurology, Christian Medical College and Hospital, Ludhiana, Punjab, India
3 Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
4 Department of Neurology, All India Institutes of Medical Sciences, New Delhi, India
5 Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
6 Department of Biostatistics, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India
7 Department of Neurology, Stroke Service, Massachusetts General Hospital, Boston, USA

Date of Submission08-May-2018
Date of Decision20-Mar-2020
Date of Acceptance21-Jun-2020
Date of Web Publication23-Dec-2021

Correspondence Address:
Dr. P N Sylaja
Comprehensive Stroke Care Program, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum - 695 011, Kerala
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.333484

Rights and Permissions

 » Abstract 

Background: Pre-stroke anti-platelet (PAP) therapy can potentially influence the severity and outcome after ischemic stroke.
Methods: We analyzed data from the prospective multicenter Indo–US collaborative stroke project for the impact of PAP therapy. Outcome measures included the admission National Institute of Health Stroke Scale (NIHSS) score, 3-month modified Rankin scale (mRS) score, and rates of in-hospital mortality and post-ischemic intracerebral hemorrhage.
Results: Among 2048 of 2066 patients (M:F = 2:1) with known pre-stroke medication status, 336 (16.3%) were on PAP therapy. As compared to the non-PAP group, the PAP group had significantly higher mean age (62.2 vs 57.4 years, P < 0.001) and significantly more men, vascular risk factors, cerebral microbleeds (12.8% vs 6.2%, P = 0.001) and intravenous thrombolysis treatment (17% vs. 10.6%, P = 0.001). Cardioembolic strokes were significantly more in the PAP group (P < 0.001), but not large artery atherosclerosis. No significant differences were observed in the median NIHSS score (9 vs. 10, P = 0.274), 3-month mRS (score 0-2,51.4% vs. 49.0%, P = 0.428), in-hospital mortality (8.6% vs. 7.8%, P = 0.592), or symptomatic post ischemic intracerebral haemorrhage (12.2% vs. 10.6%, P = 0.382). The PAP group had more stroke recurrence (6.6% vs. 2.9%, P = 0.002) which was not significant (P = 0.065) after multivariate regression analysis adjusting for age, sex and vascular risk factors. PAP therapy was not an independent predictor of initial stroke severity or stroke outcome.
Conclusion: PAP therapy has no significant effect on initial stroke severity, rates of post-ischemic hemorrhage with or without thrombolysis, in-hospital mortality, stroke recurrence, and 3-month outcome after ischemic stroke.

Keywords: Antiplatelets, outcome, stroke recurrence, stroke severity
Key Message: Pre-stroke antiplatelet therapy had no effect on the initial stroke severity, in-hospital mortality and 3-month outcome after ischemic stroke. Patients on anti-platelet therapy before stroke were older had more vascular risk factors and cerebral microbleeds.

How to cite this article:
Sylaja P N, Nair SS, Pandian J, Khurana D, Srivastava M V, Kaul S, Arora D, Sarma P S, Singhal AB. Impact of Pre-Stroke Antiplatelet Use on 3-Month Outcome After Ischemic Stroke. Neurol India 2021;69:1645-9

How to cite this URL:
Sylaja P N, Nair SS, Pandian J, Khurana D, Srivastava M V, Kaul S, Arora D, Sarma P S, Singhal AB. Impact of Pre-Stroke Antiplatelet Use on 3-Month Outcome After Ischemic Stroke. Neurol India [serial online] 2021 [cited 2022 Jan 26];69:1645-9. Available from:

Use of antiplatelet drugs in adults has progressively increased over the last three decades, particularly in persons with diabetes mellitus and cardiovascular disease.[1],[2],[3] A study from the United Kingdom reported a more than 10-fold increase in the prevalence of pre-stroke antiplatelet (PAP) use from 2.9% in 1984 to 33.6% in 2004.[3]

Premorbid therapy with antiplatelet medications can potentially influence the severity and course of acute stroke. However, mixed results have emerged from the studies exploring the effect of PAP on stroke severity. A few studies showed decreased odds of severe stroke and disability at discharge with PAP therapy[4],[5],[6],[7],[8],[9] whereas others failed to confirm these observations.[10],[11] None of the studies could demonstrate any significant impact of PAP use on the long term outcome of stroke.

All the previous studies focused on the relation of PAP therapy to stroke severity at admission and outcome at discharge. To the best of our knowledge, there are no published studies that have explored its impact on 3-month outcome. The objective of this study was to evaluate the impact of PAP on stroke severity and 3-month outcome of ischemic stroke from the data derived from a prospective multicentre stroke registry in India.

 » Methods Top

The study data were derived from the Indo-US Collaborative Stroke Project (IUCSP) which is a prospective study of acute ischemic stroke in 5 academic hospitals in India, with a coordinating center in Boston, USA.[12],[13] The study was funded by the U.S. National Institutes of Health and the Department of Biotechnology, India. The study enrolled consecutive patients 18 years and older admitted with a diagnosis of ischemic stroke within two weeks of symptom onset. Patients with primary intracranial hemorrhage, those who were discharged without admission and those who failed to give consent were excluded. The study was approved by the Ethics Committee of each hospital. Written informed consent was obtained from all participants.

Data were collected from January 2012 until December 2014 and entered in a secure web-based electronic database. Information was collected on demographics, risk factors, pre-hospital care, thrombolysis, inpatient management including quality of care, complications, laboratory test results, imaging, medications, and outcomes until 90 days. All investigators were trained and certified on the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS), trained in using the web-based 'Causative Classification of Stroke' tool ( to assign stroke mechanism, and educated to interpret brain imaging findings.

The current study analyzed the data on prior antiplatelet use among the patients recruited in this study. Patients were divided into 2 groups, PAP and non-PAP, based on documented use of antiplatelet stroke preventive medications (aspirin, dipyridamole, clopidogrel or their combinations) prior to the index stroke. Outcome measures included the 3-month mRS categorized as good (scores 0-2) or poor (scores 3-6), stroke severity at admission (as assessed by NIHSS score 0-4 versus 5+), in-hospital mortality, and symptomatic brain hemorrhage.

Statistical analysis was performed using SPSS, version 21.0 (Armonk, NY: IBM Corp). Continuous variables were expressed as mean (standard deviation) or median (interquartile range). Categorical variables were presented as numbers and percentages. Chi-square and t tests were used as appropriate. A value of P < 0.05 was considered significant. Missing data for variables were considered as being absent for analysis. Variables acquiring significance in the univariate analysis were included in a multivariable model to determine independent predictors of stroke severity, stroke recurrence, and 3-month outcome.

 » Results Top

The study recruited 2066 patients of whom 2048 with known pre-stroke medication status were included in this analysis. The mean age of the cohort was 58.25 ± 14.68 years with 1381 (67.43%) males. A total of 336 (16.3%) patients were on one or more antiplatelet medications prior to the index stroke.

[Table 1] compares the baseline clinical data between PAP and non-PAP groups. Significant differences in the vascular risk factor profile were noted between the groups. The PAP group was significantly older, had more men, had a higher prevalence of vascular risk factors, and higher rates of pre-stroke anticoagulant, antihypertensive and cholesterol-lowering medications. However, stroke severity was not significantly different between groups.
Table 1: Baseline characteristics of PAP and non-PAP group at admission

Click here to view

[Table 2] shows the treatment and outcomes of the PAP and non-PAP groups. Stroke mechanism was significantly different, with the PAP group having a higher rate of cardiac causes, but not large-artery atherosclerosis. Patients on PAP had a higher frequency of cerebral microbleeds on MRI (performed in 1376 patients), but the rates of post-ischemic hemorrhagic transformation were not significantly different. Intravenous thrombolysis was more commonly administered in the PAP group. There was no significant difference in the rate of symptomatic intracranial hemorrhage associated with thrombolysis (P = 0.884). There were no significant differences in 3-month stroke outcome or in-hospital mortality. However, a higher frequency of recurrent stroke at 90 days was noted with the PAP group.
Table 2: Inpatient and discharge features of PAP and non-PAP groups

Click here to view

[Table 3],[Table 4],[Table 5] show the results of multivariate analysis adjusting for age, sex, stroke mechanism, and vascular risk factors on outcome measures (stroke severity, 3-month outcome, and stroke recurrence). PAP therapy was not an independent predictor of stroke severity or poor outcome at 90 days, and no longer remained significant for stroke recurrence (P = 0.065, OR = 1.807, 95% CI 0.965 to 3.386).
Table 3: Logistic regression analysis for independent predictors for poor outcome (mRS 3 - 6) at 3 months

Click here to view
Table 4: Logistic regression analysis for independent predictors for initial stroke severity (NIHSS < 5)

Click here to view
Table 5: Logistic regression analysis for independent predictors for stroke recurrence

Click here to view

 » Discussion Top

A substantial part of functional recovery following stroke is achieved within three months of stroke onset and the clinical status at three months is considered a reliable predictor of the final stroke outcome.[14] Our study, which specifically addressed 3-month stroke outcome in relation to PAP use, did not demonstrate any significant effect of PAP on this measure. We also did not find any association between initial stroke severity and PAP use in our cohort. Previous studies that addressed short and long term mortality in stroke also failed to show any positive impact of PAP therapy.[5],[6] A recent study observed that the use of PAP reduced the 30-day mortality due to ischemic stroke only when dual, and not single, antiplatelet therapy was used.[9] We did not have an adequate sample size to investigate the effect of dual antiplatelet therapy in our cohort.

Predictably, the group on PAP had a significantly higher prevalence of vascular risk factors such as diabetes mellitus, hypertension, and dyslipidemia as well as higher incidence of prior stroke and myocardial infarction. These factors confer a higher risk for ongoing vascular damage and worse outcome after stroke. The higher prevalence of risk factors in the PAP group may have reduced any possible benefit of PAP therapy; however, despite adjusting for vascular risk factors we did not find any effect of PAP on stroke severity, recurrence rates and 3-month outcome. Some of the earlier studies used propensity score matching and found that the PAP use became significant for stroke severity only after accounting for the effect of risk factors.[7],[8],[15] Although risk factors account for 90% of the stroke occurrence,[16] the propensity to develop these risk factors varies between and within population groups as does the risk of recurrence.[17] Additional factors including genetic predispositions need to be explored to more definitely quantitate this risk.

The trials of low dose aspirin for primary prevention of cardiovascular diseases have shown mixed results.[18],[19],[20],[21] A consistent finding was an increased risk for hemorrhagic strokes with aspirin.[18],[19],[20],[21] Interestingly, in our cohort, those with a history of hemorrhagic stroke were also more likely to use PAP, though the absolute numbers were low, and it is possible that the past history concerning prior stroke subtype was not reliable. Both hemorrhagic and ischemic strokes share vascular risk factors like older age, male sex, and hypertension[22] and persons with intracerebral bleed may be more prone to have concomitant vascular diseases like coronary artery disease and ischemic strokes. Intracerebral hemorrhage may, therefore, be a strong marker of vascular injury.

Previous studies had noted a differential effect for PAP therapy for the various etiological subtypes of stroke.[15],[23] PAP therapy was useful in reducing the frequency and severity of strokes related to large artery atherosclerotic disease but did not significantly impact the profile of small vessel and cardioembolic strokes.[15],[23] The low number of subjects using PAP limited a subgroup analysis in this study.

As was observed in our study, previous studies also noted a significantly higher occurrence of cerebral microbleeds in antiplatelet users.[24],[25] A Japanese study had reported an association for the presence of microbleeds with dual, but not single, antiplatelet therapy.[26] A pooled analysis of similar studies did not show a difference in the number of microbleeds in antiplatelet users who developed intracerebral hemorrhage compared to those who had an ischemic stroke.[24] In this respect, antiplatelet associated microbleeds differ from those associated with warfarin therapy in that the latter portends an increased risk of an intracranial hemorrhage.[24] Our observations on cerebral microbleeds are limited by the non-availability of MRI in 32.8% of the patients and the lack of information on single versus dual antiplatelet therapy.

Our study has limitations. Some details concerning antiplatelet therapy such as the specific drug, doses of the drugs, and the number of drugs used were not available. Secondly, at the baseline, there were statistically significant differences in the risk factor profile of the PAP and non-PAP groups which could contribute to the inability to demonstrate a protective effect for PAP in these patients despite multivariable adjustment. The relatively low number of patients on PAP therapy could also have dictated the lack of significant differences in the protective effects. The low sample size also prevented us from including other potential influencers of outcome like anticoagulant and statin use and in-hospital complications in the multivariable model. Follow-up until 3 months may not be adequate to show the effects of PAP on stroke recurrence. The strength of the study was the meticulous collection of the data prospectively by trained staff with accurate documentation of the information on the risk factors, severity, and outcome of stroke. In all the centers, the NIHSS at admission and mRS on follow-up were scored by research associates with training and certification in the scoring systems.

In conclusion, our analysis did not reveal an association of PAP use with the three-month functional outcome of acute ischemic stroke. Furthermore, the higher risk for stroke recurrence in the PAP group was nullified after correcting for traditional vascular risk factors. The negative effects on the group on antiplatelet drugs may largely be related to the higher burden of vascular risk factors, but other factors such as ethnicity and genetic factors in relation to the drug effect also need to be explored.

Financial support and sponsorship

This study was supported by the US National Institutes of Health (R21NS077442) and the Department of Biotechnology, Government of India.

Conflicts of interest

Dr Singhal is consultant at Partners HealthCare International. The other authors have no conflicts of interest.

 » References Top

Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral risk factor surveillance system. Am J Prev Med 2006;30:74–7.  Back to cited text no. 1
Béjot Y, Osseby GV, Gremeaux V, Durier J, Rouaud O, Moreau T, et al. Changes in risk factors and preventive treatments by stroke subtypes over 20 years: A population-based study. J Neurol Sci 2009;287:84-8.  Back to cited text no. 2
Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363:1925–33.  Back to cited text no. 3
Wilterdink J, Bendixen B, Adams HP, Woolson RF, Clarke WR, Hansen MD. Effect of prior aspirin use on stroke severity in the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke 2001;32:2836-40.  Back to cited text no. 4
Dowlatshahi D, Hakim A, Fang J, Sharma M. Pre admission antithrombotics are associated with improved outcomes following ischaemic stroke: A cohort from the Registry of the Canadian Stroke Network. Int J Stroke 2009;4:328-34.  Back to cited text no. 5
Béjot Y, Aboa-Eboulé C, de Maistre E, Jacquin A, Troisgros O, Hervieu M, et al. Prestroke antiplatelet therapy and early prognosis in stroke patients: The Dijon Stroke Registry. Eur J Neurol 2013;20:879-90.  Back to cited text no. 6
Jung J, Choi J, Eun M, Seo W, Cho K, Yu S, et al. Prestroke antiplatelet agents in first-ever ischemic stroke. Neurology 2015;84:1–9.  Back to cited text no. 7
Park JM, Kang K, Cho YJ, Hong KS, Lee KB, Park TH, et al. Comparative effectiveness of prestroke aspirin on stroke severity and outcome. Ann Neurol 2016;79:560-8.  Back to cited text no. 8
Würtz M, Schmidt M, Grove EL, Horváth-Puhó E, Henderson VW, Christiansen CF, et al. Preadmission use of platelet inhibitors and short-term stroke mortality: A population-based cohort study. Eur Heart J Cardiovasc Pharmacother 2018;4:158-65.  Back to cited text no. 9
Karepov V, Bornstein NM, Hass Y, Korczyn AD. Does daily aspirin diminish severity of first-ever stroke? Arch Neurol 1997;54:1369–71.  Back to cited text no. 10
Ricci S, Lewis S, Sandercock P. Previous use of aspirin and baseline stroke severity: An analysis of 17,850 patients in the International Stroke Trial. Stroke 2006;37:1737-40.  Back to cited text no. 11
Khurana D, Pandian J, Sylaja PN, Kaul S, Srivastava MVP, Thakur S, et al. The Indo-US Collaborative Stroke Registry and infrastructure development project. Neurol India 2018;66:276-8.  Back to cited text no. 12
[PUBMED]  [Full text]  
Sylaja PN, Pandian JD, Kaul S, Srivastava MVP, Khurana D, Schwamm LH, et al. Ischemic stroke profile, risk factors, and outcomes in India. The Indo-US Collaborative Stroke Project. Stroke 2018;49:219-22.  Back to cited text no. 13
Jørgensen HS, Nakayama H, Raaschou HO, Vive-Larsen J, Støier M, Olsen TS. Outcome and time course of recovery in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study. Arch Phys Med Rehabil 1995;76:406-12.  Back to cited text no. 14
Kim W, Ko Y, Yang MH, Im S, Park JH, Lee JS, et al. Differential effect of previous antiplatelet use on stroke severity according to stroke mechanism. Stroke 2010;41:1200-4.  Back to cited text no. 15
O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (The INTERSTROKE study): A case-control study. Lancet 2010;376:112-23.  Back to cited text no. 16
Lisabeth LD, Smith MA, Brown DL, Moyé LA, Risser JM, Morgenstern LB. Ethnic differences in stroke recurrence. Ann Neurol 2006;60:469-75.  Back to cited text no. 17
Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129–35.  Back to cited text no. 18
de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89–95.  Back to cited text no. 19
Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–304.  Back to cited text no. 20
Uchiyama S, Ishizuka N, Shimada K, Teramoto T, Yamazaki T, Oikawa S, et al. Aspirin for stroke prevention in elderly patients with vascular risk factors. Japanese Primary Prevention Project. Stroke 2016;47:1605-11.  Back to cited text no. 21
Ariesen MJ, Claus SP, Rinkel GJE, Algra A. Risk factors for intra cerebral hemorrhage in the general population. A systematic review. Stroke 2003;34:2060-6.  Back to cited text no. 22
Jung JM, Cha J, Choi J, Eun MY, Seo WK, Oh K, et al. Pre stroke antiplatelet agents in first-time ischemic stroke are related to sub types. Eur Neurol 2016;75:89-95.  Back to cited text no. 23
Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL; Edinburgh Stroke Study Group, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: An systematic review of published and unpublished studies. Stroke 2010;41:1222-8.  Back to cited text no. 24
Vernooij MW, Haag MD, van der Lugt A, Hofman A, Krestin GP, Stricker BH, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: The Rotterdam Scan Study. Arch Neurol 2009;66:714-20.  Back to cited text no. 25
Naka H, Nomura E, Kitamura J, Imamura E, Wakabayashi S, Matsumoto M. Antiplatelet therapy as a risk factor for microbleeds in intracerebral haemorrhage patients: Analysis using specific antiplatelet agents. J Stroke Cerebrovasc Dis 2013;22:834-40.  Back to cited text no. 26


  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]


Print this article  Email this article
Online since 20th March '04
Published by Wolters Kluwer - Medknow